Previous 10 | Next 10 |
NEW YORK , June 19, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has filed a Preliminary Proxy Statement with the Securities and Exchange Commission and announced a Special Meeting of Stockholders related to approving various items related to the propos...
Spherix's investment portfolio into emerging biotech stocks has resulted in substantial gains, turning a roughly $860,000 investment into a position worth more than $11 million at current share price levels, and marking a Price to Book ratio of less than 100%; The recently announced asset-pu...
LAS VEGAS, NV / ACCESSWIRE / June 6, 2019 / In October of last year, StockLab's editorial team was introduced to Spherix Incorporated (NASDAQ: SPEX) . We were immediately intrigued by some of the medical advancements in Spherix's universe which were, well, let's just say fascinating to sa...
Gainers: Novan (NASDAQ: NOVN ) +27% . Sea Limited (NYSE: SE ) +23% . Allied Healthcare Products (NASDAQ: AHPI ) +17% . Westwater Resources (NASDAQ: WWR ) +12% . Novus Therapeutics (NASDAQ: NVUS ) +12% . Spherix Incorporated (NASDAQ: SPEX ) +11% . CSW Industrials (NASDAQ: CSWI )...
Spherix Incorporated (NASDAQ: SPEX ): Q1 GAAP EPS of -$0.57. More news on: Spherix Incorporated, Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK , May 16, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) ("Spherix" or the "Company") today announced that the Company filed its Form-10Q for the period ended March 31, 2019 , which showed total assets of $11,937,000.00 and liabilities of $982,000.00 , with 2,010,07...
NEW YORK , April 2, 2019 /PRNewswire/ -- Spherix Incorporated, (NASDAQ: SPEX) a technology development company committed to the fostering of innovative ideas, today issued a letter to shareholders: Dear Fellow Shareholder, One of the most challenging tasks as CEO is taking...
NEW YORK , March 12, 2019 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX)- a technology development company committed to the fostering of innovative ideas, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2018 with the ...
Developing treatments of eczema, which creates an economic burden estimated to be $5.3 billion, Hoth Therapeutics (HOTH) is targeting a large market. In addition, with other competitors having enterprise value of more than $300 million, HOTH seems undervalued with an enterprise value of $72.64...
NEW YORK , Oct. 29, 2018 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has added Dr. Rana Quraishi to the Company's Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area. Dr. Rana Quraishi...
News, Short Squeeze, Breakout and More Instantly...
AIkido Pharma Company Name:
SPEX Stock Symbol:
NASDAQ Market:
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Fin...
ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. ...
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC) Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin ® program in cystic fi...